RxDoctor Payments Data

Peter Calabrese, DO

Family Medicine · Chicago, ILNPI 1891766275

Payments from drug & device makers

$2,373in general payments, 2019–2025

Across 106 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$497
  • Pfizer$263
  • GSK$248
  • Mimedx Group, Inc.$154
  • E.r. Squibb & Sons, L.L.C.$146
  • AstraZeneca$143
  • plus $924 from 16 others

What the payments were for

  • Food & beverage$2,33999%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,373 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$137,845
Medicare patients
225
Services billed
1,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$53,437
FarxigaDapagliflozin Propanediol15$24,358
OzempicSemaglutide11$20,367
Humalog Kwikpen U-100Insulin Lispro14$3,856
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,758
Atorvastatin Calcium281$3,212
Tolterodine Tartrate ErTolterodine Tartrate15$2,848
Levothyroxine Sodium140$2,103
Metoprolol Succinate143$2,096
Amlodipine Besylate171$1,683
Pantoprazole Sodium87$1,439
Nebivolol Hcl15$1,414
Repaglinide19$1,329
Fesoterodine Fumarate ErFesoterodine Fumarate11$1,248
Metformin Hcl96$1,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$263$53,43750 claims
AstraZenecaFarxiga$143$24,35815 claims
Novo NordiskOzempic$497$20,36711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →